-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
the latest statistics, cancer remains a serious threat to public health worldwide and new cancer treatments are urgently needed. Currently, most clinical cancer treatments still have difficulty completely curing cancer and have serious side effects, which lead to metastasis, diffusion and drug resistance mutations. Fast, complete, targeted and safe oncology treatment remains a key issue in cancer treatment.On July 2, 2020, Zhu Yongfa of Tsinghua University and Shanyue Guan of the Institute of Science and Technology of the Chinese Academy of Sciences jointly published an online newsletter entitled "Photogenerated Holes Induced rapids of the solid tumors by the supramolecular porphyrin photoca Talyst"s research paper, which established a supermoleal photocatalyst Nano-SA-TCPP, can be irradiated at 600-700 nm wavelengths to treat solid tumors, solid tumors (100 mm3) can be eliminated in 10 minutes.The survival rate of mice increased from 0% to 100% 50 days after phototolytic therapy. The radon-based photocatalyst can be targeted by cancer cells for internalization without entering normal cells due to size selection. The treatment has no toxicity or side effects on normal cells and organisms. Moreover, phototolytic therapy is effective in a variety of cancer cell systems. Because of its high efficiency, safety and versatility, phototolytic therapy provides us with new ways to conquer tumors.According to the latest statistics, cancer remains a serious threat to public health worldwide and new cancer treatments are urgently needed. Currently, most clinical cancer treatments still have difficulty completely curing cancer and have serious side effects, which lead to metastasis, diffusion and drug resistance mutations.Nanodrives for cancer treatment have been widely used in preclinical and clinical applications, especially with phototherapy methods, to target tumors precisely and minimize damage to normal cells. Photothermal therapy (PTT) uses the photothermal effects of nanoparticles to generate local heat above 42 degrees C to kill cancer cells. PTT has some unique and fascinating advantages, such as its invasiveness and high effectiveness.However, the metals and carbon-based nanomaterials of photothermal agents (NTAs) are difficult to metabolize, leading to cumulative toxicity and permanent damage to the brain, kidneys, liver and other organs. The relatively low photothermal stability and photothermal conversion efficiency (PCE) of small organic molecules of photothermal agents (NTAs) limit their clinical application. For other PTAs, such as other inormeric 2D materials and polymer nanoparticles, the synthesis strategy is too complex and usually has a large dimensional distribution.Another clinically approved light therapy is photodynamic therapy (PDT), which kills cancer cells with photoactive photosensitivity agents (PSs) and exoactive reactive oxygen (ROS) produced by oxygen. Because ROS is a chemically reactive freelance molecule or a non-free molecule derived from an oxygen molecule, PDT is an oxygen-dependent process that destroys a variety of cancer cells. As a result, repeated PDT treatments were drug-resistant. Despite these advantages, oxidizing intermediates are often inefficient and require repeated treatment due to the need for oxidizing intermediates in the micro-environment of oxygen-deficing tumors.Photo catalysis, driven by photon energy, can oxidize or reduce substrate molecules. Recently, photocatalysts have been used in life-related antibacterial and antiviral fields, which stimulates the possible role of photocatalysts in tumor treatment. Not long ago, researchers reported on a method of preparing a supermolegisic photocatalyst for self-assembling tetrium-based benzene (SA-TCPP) and demonstrated its oxidation ability to be stimulated by light at wavelengths of 420-750nm. Molybon-based molecular drugs are widely used in PDT due to their excellent biological capacity and release of single-line oxygen, some of which have been clinically applied.It is well known that one of the obstacles to phototherapy is its depth of penetration, which is also important for detection. The red/NIR light area between 600 and 1200nm is called the optical window of the tissue and facilitates deep penetration. With this in account, the researchers attempted to use the photorespores of SA-TCPP to achieve strong oxidation killing of solid tumors and to form the Theragnostic system of cancer cells. If this idea works, it may be more effective than PDT and PPT because it does not require heat and oxygen, which is more suitable for tumor micro-environments.The study established a supermoleal photocatalyst, Nano-SA-TCPP, which can be treated at 600-700 nm wavelengths to treat solid tumors, which can be eliminated in 10 minutes. The survival rate of mice increased from 0% to 100% 50 days after phototolytic therapy. The radon-based photocatalyst can be targeted by cancer cells for internalization without entering normal cells due to size selection. The treatment has no toxicity or side effects on normal cells and organisms. Moreover, phototolytic therapy is effective for a variety of cancer cell line. Because of its high efficiency, safety and versatility, phototolytic therapy provides us with new ways to conquer tumors.
(iNature
): 1) Photogenerated holes induced rapids of the outing of solid tumors by the supramolecular porphyrin photocatalyst